CCM
OKUR

CAAS Capital Management’s OnKure Therapeutics OKUR Stock Holding History

CAAS Capital Management’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,000
Closed -$187K – 1141
2021
Q2 		$187K Buy
+2,000
New +$223K ﹤0.01% 883

Other funds holding OKUR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAAS Capital Management's OKUR Position: Q3 2021 in Review

CAAS Capital Management sold out of OnKure Therapeutics (OKUR) in Q3 2021, closing a stake of 2,000 shares — an estimated $187K sold.

CAAS Capital Management first reported a position in OKUR in Q2 2021 and held it in 1 quarter. The position peaked at $187K in Q2 2021. 38 funds tracked by Wall St. Rank hold OKUR as of Q3 2021.

  • CAAS Capital Management reported no remaining OnKure Therapeutics position as of Q3 2021 after selling out during the quarter.
  • CAAS Capital Management sold 2,000 OnKure Therapeutics shares in Q3 2021, an estimated $187K.
  • CAAS Capital Management first reported a position in OnKure Therapeutics in Q2 2021 and held it in 1 quarter.
  • CAAS Capital Management's OnKure Therapeutics position peaked at $187K in Q2 2021.
  • 38 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q3 2021.

Based on CAAS Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.